Tris Pharma $7.5 Million Texas Settlement Over Dyanavel XR, What Parents and Patients Need to Know
Tris Pharma, Inc. and CEO Ketan Mehta agreed to pay $7.5 million to the State of Texas to resolve a lawsuit accusing the pharmaceutical company of making misleading claims about the effectiveness of Dyanavel XR, an ADHD medication. The settlement does not create a consumer class action, settlement fund or claim program. Patients and parents…
